Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Collegium and Grünenthal settle Nucynta patent litigationOct 19PartnershipCollegium Pharmaceutical, IncGrünenthal
Collegium cuts 2026 revenue guidance on weaker Nucynta generic pricingAug 6Quarterly updateCollegium Pharmaceutical, Inctapentadol